Ucb SA
XBRU:UCB
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
129.35
260.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
UCB
stock under the Base Case scenario is
230.37
EUR.
Compared to the current market price of 227.9 EUR,
Ucb SA
is
Undervalued by 1%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Ucb SA.
| US |
|
Eli Lilly and Co
NYSE:LLY
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Revenue & Expenses Breakdown
Ucb SA
Balance Sheet Decomposition
Ucb SA
| Current Assets | 5.3B |
| Cash & Short-Term Investments | 2B |
| Receivables | 1.9B |
| Other Current Assets | 1.4B |
| Non-Current Assets | 11.9B |
| Long-Term Investments | 290m |
| PP&E | 1.8B |
| Intangibles | 8.6B |
| Other Non-Current Assets | 1.2B |
| Current Liabilities | 3.9B |
| Accounts Payable | 3.2B |
| Other Current Liabilities | 734m |
| Non-Current Liabilities | 3.6B |
| Long-Term Debt | 2.8B |
| Other Non-Current Liabilities | 756m |
Free Cash Flow Analysis
Ucb SA
| EUR | |
| Free Cash Flow | EUR |
Earnings Waterfall
Ucb SA
|
Revenue
|
6.8B
EUR
|
|
Cost of Revenue
|
-1.8B
EUR
|
|
Gross Profit
|
5B
EUR
|
|
Operating Expenses
|
-3.2B
EUR
|
|
Operating Income
|
1.8B
EUR
|
|
Other Expenses
|
-488m
EUR
|
|
Net Income
|
1.3B
EUR
|
UCB Profitability Score
Profitability Due Diligence
Ucb SA's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Score
Ucb SA's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
UCB Solvency Score
Solvency Due Diligence
Ucb SA's solvency score is 72/100. The higher the solvency score, the more solvent the company is.
Score
Ucb SA's solvency score is 72/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
UCB Price Targets Summary
Ucb SA
According to Wall Street analysts, the average 1-year price target for
UCB
is 252.28 EUR
with a low forecast of 148.47 EUR and a high forecast of 315 EUR.
Dividends
Current shareholder yield for
UCB is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
UCB
stock under the Base Case scenario is
230.37
EUR.
Compared to the current market price of 227.9 EUR,
Ucb SA
is
Undervalued by 1%.